Form 4: Ionis Pharmaceuticals Director Joan Herman Reports RSU Vesting and Share Acquisition

Ionis Pharmaceuticals Director Joan E. Herman reported the acquisition of 4,079 shares of common stock through the vesting of Restricted Stock Units on July 15, 2025, increasing her direct beneficial ownership to 46,086 shares.

Summary

• Joan E. Herman, a Director of Ionis Pharmaceuticals Inc. (IONS), reported a transaction on July 15, 2025.
• She acquired 4,079 shares of common stock through the vesting and release of a Restricted Stock Unit (RSU) award.
• The acquisition price for these shares was $0.0, as they were received upon vesting of RSUs.
• Following this transaction, Ms. Herman directly beneficially owns 46,086 shares of Ionis common stock.
• Additionally, she holds 5,220 Restricted Stock Units, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine insider transaction (vesting of RSUs), which is expected. The increase in direct ownership by a director is generally viewed positively as it aligns interests, but it's not a discretionary purchase.

Positives

• Director Joan E. Herman increased her direct beneficial ownership of Ionis Pharmaceuticals common stock by 4,079 shares, demonstrating continued alignment with shareholder interests.
• The vesting of Restricted Stock Units indicates the fulfillment of long-term incentive compensation, which is a standard practice for retaining and incentivizing key personnel.

Future Outlook

The document details the vesting schedule for Restricted Stock Units, indicating that RSUs vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, with delivery on the July 15th following the vesting date.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Ionis Pharmaceuticals, where equity compensation is a standard component of executive and director remuneration.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation, with a vesting schedule tied to service, is a common practice for director compensation in the biotechnology and pharmaceutical industry, aligning director incentives with long-term company performance.
• Companies such as Amgen, Gilead Sciences, and Biogen frequently utilize similar equity-based compensation structures for their non-employee directors.

Stakeholder Impact

• Shareholders: The increase in director ownership through RSU vesting aligns the director's interests with shareholders, potentially fostering long-term value creation.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Director Compensation, Equity Compensation, Joan Herman